Repeated measurements of IL-6 suggest that persistent systemic inflammation is independently associated with increased mortality in apixaban treated AF patients, even after considering established clinical risk factors and other strong cardiovascular biomarkers. The gene discussed is IL6; the disease is atrial fibrillation.